← Return to What do you all think of #Social Media Listening ?

Discussion
Comment receiving replies
@nyxygirl

"No worries ... I was hoping health care providers were reading our posts."-- ha ha LOL - me too !! I did a little more digging around . I am still intrigued a bit about their particular choice of PMR and GCA . Of all the Rheumatic diseases to chose, maybe juvenile arthritis would have a lot of social media posts all over the place !! ; )

That said - I'll attach a compilation of what I remember from some of the manuscripts that included patient opinions or real time cohort data.
In the Methods , an ethics committee was mentioned, or that data were anonymized . I recalled in particular an Op Ed about a PMR patient's perspective is super interesting. He used a 4000 member FACEBOOK group . I'll attach that.

I guess my thought is that this Novartis poster has such disclaimers about Ethics approvals and/or other details about the methods . And perhaps which specific "social Media" platforms were searched.

Jump to this post


Replies to ""No worries ... I was hoping health care providers were reading our posts."-- ha ha LOL..."

The following studies might have something to do with the interest that Novartis has in PMR/GCA. They must be seeing good results:
https://www.novartis.com/clinicaltrials/study/nct06130540
and
https://www.novartis.com/clinicaltrials/study/nct06331312
---------------------------
My rheumatologist has already mentioned COSENTYX® (secukinumab) to me because I have Spondyloarthritis and PMR.
--------------------------
I loved this part of the abstract:

"Sentiment of pts around various treatments (n=297) available for PMR and GCA was negative (61%), mostly driven by side effects/intolerability, inefficacy/waning efficacy and flare-ups during steroid tapering. From the overall responses related to treatment perceptions (n=41), glucocorticoids (GC) had a relatively negative perception (35%), whereas biologics had a more positive perception (27%) and were perceived as a safer alternative by pts. The burden of comorbidities associated with the use of GCs was also a recurrent concern."